HBV related Liver disease is a common medical problem in China. An estimated 7.18% of the
Chinese (about 93 million) is infected with hepatitis B, and most of the HBV- related
hepatitis can developed into liver cirrhosis.
Liver transplantation is the only available life saving treatment for patients with end stage
liver disease. However, lack of donors, surgical complications, rejection, and high cost are
Mesenchymal stem cells (MSCs) possess plasticity and have the potential to differentiate into
hepatocyte; Thus, MSCs hold great hope for therapeutic applications. Human umbilical
cord-derived MSCs (hUC-MSCs) exhibit a more beneficial immunogenic profile and greater
overall immunosuppressive potential than aged bone marrow-derived MSCs. Like MSCs derived
from bone marrow, hUC-MSCs can also be used to treat rat liver fibrosis and improve glucose
homeostasis in rats with liver cirrhosis. In this study, the patients with HBV-related liver
cirrhosis will undergo administration of hUC-MSCs via hepatic artery to evaluate the safety
and efficacy of hUC-MSC treatment for these patients.